API
< Back to all clusters
[HEALTH] · 2 sources

started · updated

Multiple sclerosis research shifts toward immune reconstitution therapies

Research into multiple sclerosis (MS) is shifting toward a tolerance-centric paradigm to better manage the neurodegenerative autoimmune disease. Current approaches distinguish between continuous maintenance disease-modifying therapies (DMTs), which suppress inflammation during administration, and immune reconstitution therapies (IRTs).

IRTs, such as alemtuzumab, cladribine, and autologous hematopoietic stem cell transplantation (aHSCT), aim for a durable immune reset. These therapies work through finite lymphocyte depletion followed by a qualitative immune repopulation that favors regulatory cells over pathogenic clones. Emerging next-generation cell-based therapies, including tolerogenic dendritic cells and mesenchymal stromal cells, seek to induce precision, antigen-specific tolerance to minimize the need for chronic systemic immunosuppression.

Entities

Thomas Jefferson University